Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Five Prime Thera
(NQ:
FPRX
)
22.31
USD
-1.12 (-4.78%)
Official Closing Price
Updated: 6:23 PM EST, Mar 2, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Five Prime Thera
< Previous
1
2
3
4
5
6
7
8
9
Next >
Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call
Today 16:05 EST
Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call
From
Business Wire News Releases
Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
February 26, 2021
Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
From
Business Wire News Releases
Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
February 22, 2021
Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
From
Business Wire News Releases
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day
February 05, 2021
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day
From
Business Wire News Releases
Thinking about buying stock in Obseva SA, DBV Technologies, BlackBerry, Five Prime Therapeutics, or BioNano Genomics?
January 15, 2021
InvestorsObserver issues critical PriceWatch Alerts for OBSV, DBVT, BB, FPRX, and BNGO.
From
PR Newswire
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ G
January 15, 2021
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemo
From
Business Wire News Releases
Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?
January 05, 2021
InvestorsObserver issues critical PriceWatch Alerts for ZOM, ZSAN, MRKR, FPRX, and INUV.
From
PR Newswire
Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium
December 09, 2020
Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology Gastrointestinal Cancers Annual Symposium
From
Business Wire News Releases
Five Prime Announces Closing of Upsized Public Offering of Common Stock
November 17, 2020
Five Prime Announces Closing of Upsized Public Offering of Common Stock
From
Business Wire News Releases
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
November 12, 2020
Five Prime Therapeutics, Inc. (Nasdaq: FPRX), announced today the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share. The...
From
Business Wire News Releases
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
November 11, 2020
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
From
Business Wire News Releases
Five Prime Announces Proposed Public Offering of Common Stock
November 11, 2020
Five Prime Announces Proposed Public Offering of Common Stock
From
Business Wire News Releases
Thinking about buying stock in Five Prime Therapeutics, Ford, Laredo Petroleum, Electrameccanica Vehicles, or Nvidia?
November 11, 2020
InvestorsObserver issues critical PriceWatch Alerts for FPRX, F, LPI, SOLO, and NVDA.
From
PR Newswire
Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-
November 10, 2020
From
GlobeNewswire News Releases
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gas
November 10, 2020
Five Prime Announces Bemarituzumab Plus Chemo Demonstrates Significant PFS and OS Benefit Compared to Placebo Plus Chemo in Front-line Gastric Cancer
From
Business Wire News Releases
Five Prime Therapeutics Reports Third Quarter 2020 Results
November 03, 2020
Five Prime Therapeutics Reports Third Quarter 2020 Results
From
Business Wire News Releases
Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting
November 02, 2020
Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting
From
Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call
October 27, 2020
Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call
From
Business Wire News Releases
Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
September 18, 2020
Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
From
Business Wire News Releases
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
September 09, 2020
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
From
Business Wire News Releases
Bullish stock with Increased Insider Transactions: $HROW $FPRX $INFN
September 03, 2020
Tags
The Market Signal
From
The Market Signal
Five Prime Therapeutics Reports Second Quarter 2020 Results
August 06, 2020
Five Prime Therapeutics Reports Second Quarter 2020 Results
From
Business Wire News Releases
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
July 29, 2020
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
From
Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call
July 29, 2020
Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call
From
Business Wire News Releases
Five Prime Therapeutics Reports First Quarter 2020 Results
May 07, 2020
Five Prime Therapeutics Reports First Quarter 2020 Results
From
Business Wire News Releases
Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call
April 30, 2020
Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call
From
Business Wire News Releases
Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format
April 22, 2020
Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format
From
Business Wire News Releases
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
April 14, 2020
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
From
Business Wire News Releases
Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
March 13, 2020
Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
From
Business Wire News Releases
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
February 27, 2020
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.